Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease.

Department of Human Biology, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue, Seattle, WA 98109-1024, USA.
The Journal of Infectious Diseases (Impact Factor: 5.78). 04/2003; 187(5):741-7. DOI: 10.1086/374273
Source: PubMed

ABSTRACT Transmission of human immunodeficiency virus type 1 (HIV-1) via breast-feeding can occur throughout lactation. Defining both fluctuation in breast-milk virus level over time and how breast-milk virus correlates with mother-to-child transmission is important for establishing effective interventions. We quantified breast-milk HIV-1 RNA levels in serial samples collected from 275 women for up to 2 years after delivery. Higher maternal plasma virus load, lower maternal CD4 T cell count, and detection of HIV-1 DNA in maternal genital secretions were significantly associated with elevated breast-milk HIV-1 RNA. Within women who breast-fed, median virus load in colostrum/early milk was significantly higher than that in mature breast milk collected 14 days after delivery (P< or =.004). Breast-feeding mothers who transmitted HIV-1 to their infants had both significantly higher breast-milk viral RNA throughout lactation and more-consistent viral shedding, compared with mothers who did not transmit HIV-1. In breast-feeding women, a 2-fold-increased risk of transmission was associated with every 10-fold increase in breast-milk virus load (95% confidence interval, 1.3-3.0; P<.001). These results indicate that the risk of infant infection from breast-feeding is influenced by breast-milk virus load, which is highest early after delivery.


Available from: Grace John-Stewart, Jun 12, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Worldwide every year approximately 750,000 children become infected with HIV, mostly through mother-to-child transmission (MTCT). Without specific interventions, the rate of MTCT is approximately 15-20%, with prolonged breastfeeding doubling the rate to 35-40%. Current approaches to intervention to reduce the risk of MTCT focus mainly on antiretroviral prophylaxis during pregnancy, labour and in the early neonatal period, but in some settings also on delivery procedures and avoidance of breastfeeding. To reduce the risk of breastfeeding transmission, shortening the breastfeeding period and/or encouraging exclusive breastfeeding has been suggested. MTCT rates of less than 2% are now reported from countries where antiretroviral prophylaxis, elective Caesarean section and refraining from breastfeeding can be applied, whilst in settings where refraining from breastfeeding is not feasible or safe and where elective Caesarean section is also not a safe option, peripartum antiretroviral therapy can halve the risk to levels of approximately 10% at 6 weeks, although further acquisition of infection through breastfeeding substantially increases the overall rate to 20% or more. In light of the high mortality in all children of HIV-infected women, programmes for prevention of MTCT should be monitored not only in terms of HIV transmission avoided but also in terms of child survival.
    Transactions of the Royal Society of Tropical Medicine and Hygiene 02/2006; 100(1):1-5. DOI:10.1016/j.trstmh.2005.05.012 · 1.93 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Globally, more than 2000 children under 15 years of age are infected with HIV-1 every day. Some of these infections occur in utero, but the majority of children become infected at delivery and after birth through breast-feeding. While success of antiretroviral therapy dramatically decreased mother-to-child transmission in developed countries, antiretroviral drugs are not yet widely available and bottle-feeding is not an option in economically impoverished countries, where burden of HIV-1 infections is the highest. There, effective accessible HIV-1 vaccines limiting spread of HIV-1 in adults and preventing infection of neonates through breast-feeding are urgently needed. For infant vaccines, given the difficulties in inducing widely cross-reactive HIV-1-neutralizing antibodies, effort has now shifted towards elicitation of cell-mediated immunity, likely in a combination with passively infused neutralizing antibodies and/or chemoprophylaxis. This review discusses prospects of the T-cell approach for development of a paediatric HIV-1 vaccine.
    Folia biologica 02/2004; 50(3-4):100-6. · 0.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A successful HIV-1 vaccine must elicit immune responses that impede mucosal virus transmission, though functional roles of protective HIV-1 Envelope (Env)-specific mucosal antibodies remain unclear. Colostrum is a rich source of readily accessible mucosal B cells that may help define the mucosal antibody response contributing to prevention of postnatal HIV-1 transmission. To examine the HIV-1 Env-specific colostrum B-cell repertoire, single B cells were isolated from 17 chronically HIV-infected, lactating women, producing 51 blood and 39 colostrum HIV-1 Env-specific B-cell antibodies. All HIV-1 Env-specific colostrum-derived antibodies were immunoglobulin (Ig)G1 isotype and had mean heavy chain complementarity-determining region 3 (CDR3) lengths and mutation frequencies similar to those isolated from blood. However, variable heavy chain (VH) gene subfamily 1(∼)69 usage was higher among colostrum than blood HIV-1 Env-reactive antibodies (49% vs. 20%, P=0.006, Fisher's exact test). Additionally, more HIV-1 Env-specific colostrum antibodies were gp120 specific than those isolated from blood (44% vs. 16%, P=0.005, Fisher's exact test). One cross-compartment HIV-1 Env-specific clonal B-cell lineage was identified. These unique characteristics of colostrum B-cell antibodies suggest selective homing of HIV-1-specific IgG1-secreting memory B cells to the mammary gland and have implications for targeting mucosal B-cell populations by vaccination.Mucosal Immunology advance online publication, 6 August 2014; doi:10.1038/mi.2014.69.
    Mucosal Immunology 08/2014; 8(2). DOI:10.1038/mi.2014.69 · 7.54 Impact Factor